Clover Biopharmaceuticals lands $43 mln Series B
China-based Clover Biopharmaceuticals, a clinical-stage biotechnology company, has raised $43 million in Series B financing.
China-based Clover Biopharmaceuticals, a clinical-stage biotechnology company, has raised $43 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination